Global Multiple Myeloma Market to grow at a CAGR of 4.8% and reach $ Global Multiple Myeloma Market to grow at a CAGR o | Page 2

According to the report “Global Multiple Myeloma Market" published by Market Data
Forecast, the global market is projected to reach USD 9.1 billion by 2021 from USD 7.2
billion in 2016, at a CAGR of 4.8%.
Multiple Myeloma is a rare form of cancer caused due to malignant plasma cells. When
plasma cells become cancerous, they produce a tumour called plasmacytoma. If someone
has more than one plasmacytoma, they have multiple myeloma. This is essentially a
treatable cancer. DNA alterations, Stem cell transplants, Radiation therapy and surgeries are
the available treatment options for multiple myeloma. The other factors which can have a
significant impact on multiple myeloma treatment are age and general health, results of
laboratory and cytogenetic (genomic) tests, symptoms and disease complications, prior
myeloma treatment, patient’s lifestyle, goals, views on quality of life, and personal
preferences.
Request Free Sample: http://www.marketdataforecast.com/market-reports/global-
multiple-myeloma-therapeutics-market-858/request-sample
The factors influencing the Global Market for Multiple Myeloma Therapeutics Market, either
positively or negatively are presented in the DROC analysis. The market for multiple
myeloma therapeutics is anticipated to grow with increasing incidences of the disease
among population. Growing geriatric population across the globe is absolutely augmenting
the growth of multiple myeloma therapeutics market during the forecast period. However,
various patients suffer decline or ripen treatment resistance which is acting as a restrain for
the market and it becomes necessary to develop harmless and effective treatments that
extend the duration of retardation and increase survival.
For granular level understanding, the Multiple Myeloma Market is segmented based on the
following categories with Market Size Estimations and Y-o-Y Forecasts presented for each
sub-segments.
1) By Treatment Type





Chemotherapy
Anthracycline antibiotic
Alkylating agent
Targeted Therapy
Proteasome inhibitor
2) By Drug Type





Corticosteroids
Dexamethasone (Decadron)
Prednisone (Deltasone/Orasone)
Immunomodulatory agents
Thalidomide (Thalomid)